Literature DB >> 17610414

4IgB7-H3 is the major isoform expressed on immunocytes as well as malignant cells.

Y-H Zhou1, Y-J Chen, Z-Y Ma, L Xu, Q Wang, G-B Zhang, F Xie, Y Ge, X-F Wang, X-G Zhang.   

Abstract

Human B7-H3, a novel member of B7 family, has two isoforms (2IgB7-H3 and 4IgB7-H3). As costimulatory functions of both isoforms are not clarified, there has been much discussion on their expression patterns, T-cell responses, etc. This study generated two specific mouse anti-human 2IgB7-H3 monoclonal antibodies (mAbs) (7D7 and 10F1), whose specificities are quite different from those of the available B7-H3 mAb (21D4) by competition assay. The use of antibodies indicated that B7-H3 was found to have different expression patterns on monocyte-derived dendritic cells, that is the isoform 2IgB7-H3 is tended to express on immature dendritic cells (iDCs), whereas 4IgB7-H3 could be detected in the whole process of maturation of dendritic cells. The isoform 4IgB7-H3 was shown in the immunohistochemistry assay to be more widely expressed than 2IgB7-H3 in human benign and malignant hepatic tissues. Furthermore, flow cytometry and reverse transcription-polymerase chain reaction indicated that 4IgB7-H3 rather than 2IgB7-H3 was the major isoform on many human tumor cell lines. In addition, both 2IgB7-H3- and 4IgB7-H3-transfected cells could promote T-cell proliferation, which could be blocked by 7D7 mAb. These two novel antibodies may shed light on the function of the two B7-H3 isoforms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17610414     DOI: 10.1111/j.1399-0039.2007.00853.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  17 in total

1.  Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.

Authors:  Hiroko Kobori; Masaaki Hashiguchi; Jinhua Piao; Moriyuki Kato; Patcharee Ritprajak; Miyuki Azuma
Journal:  Immunology       Date:  2010-02-05       Impact factor: 7.397

2.  Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α.

Authors:  Sangbin Lim; Hao Liu; Luciana Madeira da Silva; Ritu Arora; Zixing Liu; Joshua B Phillips; David C Schmitt; Tung Vu; Steven McClellan; Yifeng Lin; Wensheng Lin; Gary A Piazza; Oystein Fodstad; Ming Tan
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

3.  B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer.

Authors:  Hong Xu; Xiaoling Chen; Min Tao; Kai Chen; Chen Chen; Gang Xu; Wei Li; Suxu Yuan; Yixiang Mao
Journal:  Oncol Lett       Date:  2016-01-19       Impact factor: 2.967

4.  Preferential Induction of the T Cell Auxiliary Signaling Molecule B7-H3 on Synovial Monocytes in Rheumatoid Arthritis.

Authors:  Bo Ruem Yoon; Yeon-Ho Chung; Su-Jin Yoo; Kenji Kawara; Jinhyun Kim; In Seol Yoo; Chung-Gyu Park; Seong Wook Kang; Won-Woo Lee
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

5.  Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses.

Authors:  Masaaki Hashiguchi; Hiroko Kobori; Patcharee Ritprajak; Yosuke Kamimura; Haruo Kozono; Miyuki Azuma
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-23       Impact factor: 11.205

6.  B7-H3, Negatively Regulated by miR-128, Promotes Colorectal Cancer Cell Proliferation and Migration.

Authors:  Xiaomao Hu; Minxian Xu; Yangzhi Hu; Na Li; Lei Zhou
Journal:  Cell Biochem Biophys       Date:  2021-03-20       Impact factor: 2.194

7.  Origination of new immunological functions in the costimulatory molecule B7-H3: the role of exon duplication in evolution of the immune system.

Authors:  Jing Sun; Fengqing Fu; Wenchao Gu; Ruhong Yan; Guangbo Zhang; Zhiyong Shen; Yinghui Zhou; Han Wang; Bairong Shen; Xueguang Zhang
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

8.  Cloning and characterization of porcine 4Ig-B7-H3: a potent inhibitor of porcine T-cell activation.

Authors:  Weiwei Chen; Zhibo Hou; Chunman Li; Sheng Xiong; Henggui Liu
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

Review 9.  Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3.

Authors:  Nan Li; Madeline R Spetz; Dan Li; Mitchell Ho
Journal:  Pharmacol Ther       Date:  2021-05-14       Impact factor: 13.400

10.  B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.

Authors:  Yixiang Mao; Wei Li; Kai Chen; Yufeng Xie; Qiang Liu; Min Yao; Weiming Duan; Xiumin Zhou; Rongrui Liang; Min Tao
Journal:  Oncotarget       Date:  2015-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.